Official recall record

VITROS Chemistry Products CKMB Slides

What the authority reported

Per the VITROS CKMB slides instructions for use (IFU) "principles of the procedure" section, the spread layer of the CKMB slide contains goat antihuman CK-mm antibodies, which inhibit CK-mm (muscle) activity and ~50% of the CK-mb (heart) activity. The remaining CK activity represents 50% of the total CK-mb isoenzyme activity plus any CK-bb (which is relatively rare). Per the current VITROS CKMB slides IFU "known interferences" section, a total CK activity greater than 1000 u/l may result in falsely elevated CK-mb results. It is limited at 1000 u/l by design, which is due to the level of goat antihuman CK-mm antibodies added during manufacturing. Samples with total CK >1000 u/l should be diluted prior to analysis. Therefore, CK will not typically impact VITROS CKMB results below the CK result of 1000 u/l. Ortho Clinical Diagnostics (Quidelortho) has confirmed the issue and determined that lots manufactured from coating 0261 of VITROS CKMB slides do not adequately inhibit CK-mm up to a total CK >1000 u/l (as stated in the IFU). Recall Start Date: October 30, 2023

What to do

Follow the instructions in the official notice — recall remedies (refund, repair, replacement, or disposal) are defined by the issuing authority and the responsible business, and they differ per recall. Do not rely on summaries, including this one.

More recalls: Health Canada — Medical Devices · Canada · all filters